JANUVIA, JANUMET, BYETTA,
AND VICTOZA ATTORNEYS

Type 2 diabetes is a condition affecting approximately 27 million people in the United States. While there are several types of treatment for type 2 diabetes on the market, incretin mimetics drugs are a 9-billion-dollar business and are prescribed to thousands of patients every year. If you're an adult living with type 2 diabetes, the last thing you should have to worry about is potentially life-threatening side effects from your medication. However, studies have found that type 2 diabetes patients taking incretin mimetics drugs like Januvia®, Victoza®, Janumet®, and Byetta® are more likely to develop acute pancreatitis or pancreatic cancer - a particularly aggressive form of cancer that is most often fatal.

If you or someone you love took Januvia, Janumet, Byetta, or Victoza and suffered serious side effects, including pancreatic cancer or pancreatitis, you may be entitled to compensation from the manufacturer. At Grimes Teich Anderson, we are involved in litigation against pharmaceutical drug companies. Our attorneys have assisted victims and their family members in recovering compensation to cope with the damages associated with these dangerous drugs.*

Incretin mimetics are drugs that mimic the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal. They are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. Numerous studies have shown that there may be a significantly increased risk of pancreatic cancer associated with the use of certain incretin-based medications. Despite these studies, drugmakers continue to market these potentially dangerous drugs throughout the United States. Adults with type 2 diabetes who have taken or are currently taking the medications listed below are at an increased risk of developing pancreatitis and pancreatic cancer.

JANUVIA (SITAGLIPTIN)

Manufactured by Merck, Januvia (generically known as sitagliptin) is advertised as a once-daily prescription medication that assists adults with type 2 diabetes reduce their blood sugar levels. According to the numerous lawsuits against Merck, Merck allegedly failed to sufficiently test Januvia and could not provide adequate risk information to the FDA, healthcare professionals, and patients. In 2009, the FDA revised the prescribing information for Januvia, warning doctors and patients about the increased risk of pancreatitis. 

JANUMET (SITAGLIPTIN AND METFORMIN)

Janumet, also manufactured by Merck, is a combination of the drug sitagliptin and metformin. Janumet is promoted as a prescription medication in tablet form for daily use along with diet and exercise to lower blood sugar among adults with type 2 diabetes.

VICTOZA (LIRAGLUTIDE)

Manufactured by Novo Nordisk, Victoza (generically known as liraglutide) is a once-daily injectable medicine to help treat adults with type 2 diabetes by lowering blood sugar levels. Victoza is linked to a higher risk of pancreatitis and the development of medullary thyroid cancer. The FDA has demanded Nova Nordisk complete a 5-year study to analyze the risk of developing certain cancers with long-term use.

BYETTA (EXENATIDE)

Byetta is a once-a-day injectable medicine prescribed to help adults with type 2 diabetes control their blood sugar levels. Amylin Pharmaceuticals manufactures Byetta, also called Exenatide, allegedly failed to test Byetta properly before bringing it to market and then failed to provide enough information to the FDA about the drug's risks.